NCT00414622已完成2 期
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
CoMentis1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- CDR
研究概览
简要总结
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
详细描述
A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •probable Alzheimer
排除标准
- 未提供
结局指标
主要结局
CDR
次要结局
- ADAS-cog
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Phase 1a Study in Healthy ParticipantsHealthyNCT05953506Jiangsu Hansoh Pharmaceutical Co., Ltd.52
已完成
2 期
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.Covid19NCT04847544Aldeyra Therapeutics, Inc.11
已完成
1 期
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy VolunteersInfluenzaAcute Respiratory InfectionNCT03459391PHARMENTERPRISES LLC32
已完成
1 期
XC8 Safety, Tolerability and Pharmacokinetics in Healthy VolunteersAsthmaNCT03441815PHARMENTERPRISES LLC28
已完成
1 期
A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy MenParkinson's DiseaseNCT01634568Vernalis (R&D) Ltd49